Literature DB >> 16215431

Non-invasive neoplasia of the stomach.

Massimo Rugge1, Donato Nitti, Fabio Farinati, Francesco di Mario, Robert M Genta.   

Abstract

Invasive gastric cancer is the final step of a cascade of genomic and phenotypic changes, which have been defined as multistep oncogenesis. This process includes a continuum of progressively dedifferentiated phenotypes, which may result in a biologically new (i.e., nuepsilonomega = neo) cell characterized by autonomous, potentially metastatic, growth (i.e., pilambdaalphazetaomega = plasia). The clinico-pathological characterization of the advanced gastric precancerous lesions has important implications for both primary and secondary cancer prevention. The WHO agency has recently redefined dysplasia as intraepithelial [i.e., non-invasive neoplasia (NiN)]; such a proposal is consistent with the biological profile of dysplasia, which shares with invasive cancer some significant molecular attributes. Long-term follow-up studies have demonstrated that, in the natural history of gastric cancer, NiN precedes invasive adenocarcinoma. In this review, the morphological features of gastric NiN are described, also illustrating differences and similarities between the current and the previously adopted histological diagnostic criteria. The molecular profile of NiN is summarized and the spectrum of the options in the clinical management of gastric NiN are reported.

Entities:  

Mesh:

Year:  2005        PMID: 16215431     DOI: 10.1097/00042737-200511000-00007

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  7 in total

1.  Premalignant lesions in gastric cancer.

Authors:  Kazuo Yashima; Shuji Sasaki; Masaharu Koda; Koichiro Kawaguchi; Kenichi Harada; Yoshikazu Murawaki
Journal:  Clin J Gastroenterol       Date:  2009-12-16

2.  Diagnosis of gastric epithelial neoplasia: Dilemma for Korean pathologists.

Authors:  Joon Mee Kim; Mee-Yon Cho; Jin Hee Sohn; Dae Young Kang; Cheol Keun Park; Woo Ho Kim; So-Young Jin; Kyoung Mee Kim; Hee Kyung Chang; Eunsil Yu; Eun Sun Jung; Mee Soo Chang; Jong Eun Joo; Mee Joo; Youn Wha Kim; Do Youn Park; Yun Kyung Kang; Sun Hoo Park; Hye Seung Han; Young Bae Kim; Ho Sung Park; Yang Seok Chae; Kye Won Kwon; Hee Jin Chang
Journal:  World J Gastroenterol       Date:  2011-06-07       Impact factor: 5.742

3.  Argon plasma coagulation is safe and effective for treating smaller gastric lesions with low-grade dysplasia: a comparison with endoscopic submucosal dissection.

Authors:  Se Jin Jung; Soo-Jeong Cho; Il Ju Choi; Myeong-Cherl Kook; Chan Gyoo Kim; Jong Yeul Lee; Sook Ryun Park; Jun Ho Lee; Keun Won Ryu; Young-Woo Kim
Journal:  Surg Endosc       Date:  2012-10-18       Impact factor: 4.584

Review 4.  Current Management of Benign Epithelial Gastric Polyps.

Authors:  Antonio R Cheesman; David A Greenwald; Shailja C Shah
Journal:  Curr Treat Options Gastroenterol       Date:  2017-12

Review 5.  Diagnosis and management of gastric dysplasia.

Authors:  Jae Kyu Sung
Journal:  Korean J Intern Med       Date:  2016-02-26       Impact factor: 2.884

6.  Role of magnifying endoscopy with narrow-band imaging in the diagnosis of noninvasive gastric neoplasia.

Authors:  Keisuke Tanaka; Shinya Maekawa; Takashi Yoshida; Tatsuya Yamaguchi; Shinichi Takano; Shuya Matsuda; Hiroshi Hayakawa; Yasuaki Ishida; Masaru Muraoka; Satoshi Kawakami; Yoshimitsu Fukasawa; Toru Kuno; Fumihiko Iwamoto; Yuya Tsukui; Shoji Kobayashi; Yukiko Asakawa; Hiroko Shindo; Mitsuharu Fukasawa; Yasuhiro Nakayama; Taisuke Inoue; Tomoyoshi Uetake; Masahiko Ohtaka; Tadashi Sato; Kunio Mochizuki; Nobuyuki Enomoto
Journal:  JGH Open       Date:  2021-02-26

7.  Analysis of factors associated with local recurrence after endoscopic resection of gastric epithelial dysplasia: a retrospective study.

Authors:  Min Kyung Back; Hee Seok Moon; In Sun Kwon; Jae Ho Park; Ju Seok Kim; Sun Hyung Kang; Jae Kyu Sung; Eaum Seok Lee; Seok Hyun Kim; Byung Seok Lee; Hyun Yong Jeong
Journal:  BMC Gastroenterol       Date:  2020-05-12       Impact factor: 3.067

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.